Lipidologist🩺🧬 @nyulangone @NYUCVDPrevent PastPresident @NationalLipid & @LipidBoard President @NLAFoundation Dir. @BHLipidClinic T/RT≠endorsements/med advice
New York, NY
Joined May 2009
- Tweets22.4K
- Following8.5K
- Followers13.8K
- Likes30.5K
Wonderful installment of #LipidsMadeSimple by @nationallipid Drs @CBallantyneMD @MarlysLPA lipid.org/wp-content/uploads… Lipoprotein(a) @NYUCVDPrevent
Dr. James Underberg retweeted
In honor of #CholesterolMonth, the NLA is proud to release the second installment of the Lipids Simplified Series: Lipoprotein(a) Management Simplified.
Following the success of our LDL-C Management Simplified publication, we felt there was no more timely or necessary topic to tackle next than Lp(a).
Authored by leading Lp(a) experts Marlys L. Koschinsky, PhD, FNLA and Christie M. Ballantyne, MD, MNLA, this article and accompanying infographic are designed to distill the complexity surrounding Lp(a) into clear, actionable guidance for clinicians. Our goal is simple: make this essential science more accessible and easier to apply in everyday practice.
🔗 Access the full article and infographic at lipid.org/resource/lipoprote….
👉 You can find this and other NLA articles under the Articles section of our newly launched lipid.org.
Stay tuned... more topics in the Lipids Simplified Series are on the way!
#LipoproteinA #Lpa #ASCVD #CardiovascularPrevention
@CBallantyneMD @MarlysLPA
Dr. James Underberg retweeted
Congratulations to Edward A. Fisher, MD, PhD, on being selected to deliver the Russell Ross Memorial Lectureship in Vascular Biology at #AHA26 this November in Chicago.
This well-deserved honor recognizes Dr. Fisher's exceptional contributions to vascular biology.
The Lp(a) story gets more interesting every day ! Wonderful paper @Lpa_Doc
We've long focused on Lp(a) molar concentration, but Lp(a) biology is more complex. In our new paper led by Kaloyan Takov and Manual Mayr @Vascular_Prot, shows that native Lp(a) carries an APOE-associated triglyceride signature. TG(52:3) and TG(52:4), enriched in polyunsaturated fatty acids, are linked to incident MACE and may represent oxidizable lipid cargo contributing to cardiovascular risk. Lots of new stuff on the way identifying specific components of Lp(a) (chol, TG, OxPL) and CVD risk @DavidErlinge @GreggWStone @society_eas atherosclerosis-journal.com/…
Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry (LOWER) - Journal of Clinical Lipidology lipidjournal.com/article/S19… via @LipidJournal @NYUCVDPrevent @FamilyHeartFdn @foundationofnla #HoFH #FindFH
Dr. James Underberg retweeted
A topic at the forefront of lipidology: the VESALIUS-CV trial.🔬
In a new Roundtable published in @lipidjournal, Drs. Nicholas A. Marston, Robert P. Giugliano, and Kevin C. Maki dive deep into VESALIUS-CV and other clinical trials investigating intensive LDL-C reduction in high-risk patients. Together, they touch on the study designs, results, and what it all means for clinical practice.
A must-read for any clinician managing cardiovascular risk.
🔗 lipidjournal.com/article/S19…
The conversation continues at #NLAFall, October 2–4 in Orlando, where the latest clinical trial data takes center stage.
🔗 lipid.org/fall
@SystematicIRE #Lipidology #VESALIUS #CardiovascularPrevention #CardiometabolicHealth
Looking forward to chatting with my long time friend , colleague and all around great guy Dr Fred Feit this Wed Morning a 6AM on @SIRIUSXM @NYUDocs @nyulangone discussing #lipids #Lipoproteins #triglycerides @nationallipid @foundationofnla Please tune in and call in with your questions !!
Dr. James Underberg retweeted
THE LIPID THERAPEUTIC WORLD just changed. The first ORAL PCK9 inhibitor enlicitide, made by Merck, and sold as Lipfendra has arrived. Be sure to become familiar with how patients should take it. Its monthly price seems a bit lower than the injectables. The F.D.A. Approves a New Pill to Slash Cholesterol Levels nytimes.com/2026/07/16/scien… @nationallipid @ASPCardio @TheEndoSociety @FamilyHeartFdn @society_eas
Very excited to see so much interest in the field of CV Prevention and Lipidology Welcome Josh ! @NYUCVDPrevent @nationallipid @lipidboard
We’re thrilled to welcome Dr. Joshua Hyman as our newest Preventive Cardiology Fellow-the 17th fellow in our program’s history!
Dr. Hyman earned his medical degree at Yale and recently completed the Yale Internal Medicine-Pediatrics Residency Program.
med.nyu.edu/departments-inst…
Very exciting news for patients with SHTG - another option to lower triglycerides @foundationofnla @NYUCVDPrevent @Drlipid @dan_soffer
Lipid News📢: TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG).
Read the full announcement from @ionispharma: ir.ionis.com/news-releases/n…
Dr. James Underberg retweeted
One year of impact—and we’re just getting started.
The National Triglyceride Alliance was founded on a simple idea: triglycerides deserve more attention as a critical driver of cardiovascular and metabolic health.
Since then?
✔️ A growing national coalition
✔️ New education and clinical resources
✔️ Expanded awareness for patients and providers
As we approach #NationalTriglyceridesDay (March 28), we’re reminded that progress starts with awareness—and continues with action.
Let’s keep pushing forward.
Read the press release: ow.ly/NPoz50YwlrN
@SethJBaumMD @EliotBrinton @mmillermd1 @lipiddoc @ArchnaBajajMD @drmaggarwal @nationallipid @ASPCardio @NatPancFdn @livingwithfcs @TheAACE @HeartNurses @ionispharma @ArrowheadPharma @Amarincorp
#Triglycerides #Cardiology #MedEd #HealthcareInnovation
Dr. James Underberg retweeted
🙌 Today the 2026 ACC/AHA Guideline on the Management of Dyslipidemia has been released.
📍Key updates shaping contemporary lipid management:
1️⃣ Lp(a) measurement is now recommended at least once in all adults for ASCVD risk assessment.
2️⃣ PREVENT equations replace the Pooled Cohort Equations for estimating 10-year and 30-year ASCVD risk.
3️⃣ LDL-C and non-HDL-C treatment goals return as central therapeutic targets alongside percentage LDL reduction.
4️⃣ Earlier intervention is emphasized to reduce lifelong exposure to atherogenic lipoproteins.
5️⃣ Broader integration of ApoB, CAC scoring, and modern lipid-lowering therapies to refine risk stratification and treatment.
👆 An important step forward in translating decades of lipid research into clinical practice and cardiovascular prevention.
🔓 Open Access
🔗 jacc.org/doi/10.1016/j.jacc.…
@nationallipid
@society_eas
Dr. James Underberg retweeted
The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia is here, and the NLA is proud to be among the collaborating organizations.
This landmark guideline addresses evaluation, management, and monitoring of elevated cholesterol, triglycerides, and Lp(a); restores LDL-C treatment goals based on risk; and provides guidance for both adults and children across all stages of prevention.
Read the full guideline: jacc.org/doi/10.1016/j.jacc.…
Read the NLA's press release: lipid.org/nla/2026-accahamul…
#Lipidology #Dyslipidemia #Cholesterol #CardiovascularHealth
Great to share the podium @PriMedCME with my friend ,colleague , mentor and yes my PGY2 when I was an intern @BellevueHosp - and past president @nationallipid Dr Terry Jacobson - great to catch up ! @BHLipidclinic @NYUCVDPrevent
This is a wonderful program on Lipoprotein(a) Still time to register ! Happy to share @ArchnaBajajMD @PennMedicine @nationallipid @foundationofnla @FamilyHeartFdn @NYUCVDPrevent
There's still time to register! Join us on Friday for a virtual half-day Lp(a) CME symposium. Great line-up of speakers and topics and opportunities to address your questions about Lp(a). upenn.cloud-cme.com/course/c…
Dr. James Underberg retweeted
This Rare Disease Month, we’re cheering for patients on and off the field. And, tailgating the big game doesn’t have to mean high fat.🏈
Our new Buffalo Chicken Dip is low fat but still packed with flavor. So, everyone wins, no matter which team you’re cheering for!😉
Dr. James Underberg retweeted
Our annual ONLINE Foundations in Lipidology course is almost here!🧑💻
Join us in just two weeks (Feb. 16–17) for this premier introductory program designed for healthcare professionals looking to build a strong foundation in lipid management.
Led by experts in clinical lipidology, this course is a must-attend for anyone entering or advancing in the field.
🔗Register now: lipid.org/foundations
Excited to see this now available ! Please share @nationallipid @foundationofnla @FamilyHeartFdn @NYUCVDPrevent @Drlipid
NOW AVAILABLE: The NLA's Updated Clinical Guidance on Familial Hypercholesterolemia (FH)
This updated expert clinical consensus on FH reflects more than a decade of advances in screening, diagnosis, and treatment.
📄Read the full consensus statement: ow.ly/rWIg50Y5AbM
🎥Watch our CME-accredited video podcast with key authors: ow.ly/ft0R50Y5AbK
📰View the press release: ow.ly/z64U50Y5AbL
Dr. James Underberg retweeted
Join us Feb 4 for Heart Month ❤️ With the FDA’s recent removal of the black box warning on many HRTs, it’s normal to have questions about safety and heart impact.
Hear NYU experts discuss hormones and women’s #HeartHealth in this free webinar.
🔗 i.nyulangone.org/h7v
